In addition to complement components, anti-inflammatory cytokine Interleukin 1 receptor antagonist (IL1RN) was also elevated specifically in ACPA– RA, including in treatment-naïve individuals. This evidence concerns the gene PRTN3 and rheumatoid arthritis.